Emerging Technology
day one project

Section 230 Is Essential to the Internet’s Future

03.31.21 | 1 min read | Text by Sophia Cope & Ernesto Falcon & Elliot Harmon & Corynne McSherry & India McKinney & Joe Mullin

Summary

Section 230 is not a gift to Big Tech, and eliminating it will not solve the problems that Big Tech is causing. Those problems stem from a severe lack of competition. Repealing Section 230 will exacerbate those problems.

Section 230 is critical to the proper functioning of the Internet. To rein in Big Tech, the law should be supported, not weakened or repealed. The Trump Administration’s executive order on Section 230 should be repealed. Further, action to limit the power of large tech companies should be taken on three fronts: antitrust, privacy, and interoperability.

publications
See all publications
Emerging Technology
day one project
Policy Memo
An Agenda for Ensuring Child Safety in the AI Era

AI is transforming how children learn and live, and policymakers, industry, and educators owe it to the next generation to set in place a responsible policy that embraces this new technology while at the same time ensuring all children’s well-being, privacy, and safety is respected.

01.12.25 | 10 min read
read more
Emerging Technology
day one project
Policy Memo
A Peer Support Service Integrated Into the 988 Lifeline

A peer support option should be integrated into the 988 Suicide and Crisis Lifeline so that 988 service users can choose to connect with specialists based on a shared lived experience.

01.12.25 | 10 min read
read more
Emerging Technology
day one project
Policy Memo
Antitrust in the AI Era: Strengthening Enforcement Against Emerging Anticompetitive Behavior

Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.

01.10.25 | 8 min read
read more
Emerging Technology
day one project
Policy Memo
Clearing the Path for New Uses for Generic Drugs

To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.

01.09.25 | 16 min read
read more